January 13 2020 Concord, MA – Cognoptix, Inc., today announced that it has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15, during the most important week in healthcare at the Hilton San Francisco Union Square. Hilton Union Square 333 O’Farrell Street San Francisco, CA 94102
Susanne Wilke, PhD, MBA (President and CEO, Cognoptix) will be presenting at Biotech Showcase as follows:
Date: Monday, January 13, 2020
Time: 11:45 AM PST
Room: Francisco D
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
Sapphire II is an easy to use, non-invasive, eye scan test designed to aid in the early detection and diagnosis of Alzheimer’s disease (AD). This innovative technology platform combines a laser eye scanning device with an eye ointment that is highly specific for detecting β-amyloid – a protein hallmark of AD.
Phase 2 studies, along with a recently completed pre-pivotal trial, demonstrated the ability of the Sapphire II System to detect β-amyloid, with a high level of sensitivity and specificity, in the supranuclear region of lens samples from patients with AD.
Results from these two studies demonstrated strong correlation with PET scanning (the current gold standard for detecting β-amyloid in the brain) in mild AD and MCI with potentially higher sensitivity than PET in MCI subjects.
All safety standards set forth prior to study initiation were met. No serious AEs were reported during the clinical studies.
“Although we currently have excellent PET scans and CSF assays for AD biomarkers, the holy grail would be to find a highly accurate, safe, noninvasive, simple, and cost-effective diagnostic and prognostic test for AD. If further trials validate the data we have seen so far with Sapphire II, Sapphire II will meet all these market needs and could offer community-based providers an important new tool for early stage disease diagnosis and earlier interventions.” says President and CEO Susanne Wilke, Ph.D., MBA. “These are all factors that give us confidence that Sapphire II will provide a significant contribution in the field of Alzheimer’s.”
Cognoptix’s co-founder Lee Goldstein, M.D., Ph.D., who discovered Alzheimer’s disease b-amyloid pathology (Ab) in the lens of patients with the disease, says “In Alzheimer’s disease, the lens accumulates pathogenic Ab peptides as does the brain. And because the lens is transparent and optically accessible, the lens is an ideal target for very early detection of Alzheimer’s disease pathology.”
The company is currently planning for an end of phase 2 meeting with US regulatory authorities and is designing a pivotal phase 3 trial in conjunction with its scientific advisory board. It is expected the phase 3 trial will be initiated the first half of 2020.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during the course of one of the industry's largest gatherings and busiest weeks.
“We are delighted that Cognoptix will be presenting its Sapphire II System eye scan test to aid in the detection of AD at Biotech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Biotech Showcase is a prime occasion for life science entrepreneurs and investors to come together to discover the potential of innovative technologies that will drive the future of drug discovery.”
Cognoptix has scheduled a company presentation at Biotech Showcase™ 2020, to be held January 13–15 2020, during the most important week in global healthcare at the Hilton, San Francisco, CA USA
Susanne Wilke, PhD, MBA (President and CEO, Cognoptix) will be presenting at Biotech Showcase as follows:
Date: Monday, January 13, 2020
Time: 11:45 AM PST
Room: Francisco D
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 12th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
ABOUT COGNOPTIX
Cognoptix is a company dedicated to developing its Sapphire II System: an eye test to aid in the early detection and diagnosis of Alzheimer’s disease (AD) by measuring β-amyloid in the ocular lens.
The key to effective preventive therapy and treatment of Alzheimer’s is the creation of an “early warning system” for the disease, before it progresses to the point where useful interventions are limited.
It is the company’s goal to develop its platform technology as a safe, noninvasive, simple to administer, cost-effective test that offers equal (or even greater) sensitivity and specificity compared with currently available PET brain scans for detecting the β-amyloid hallmark of AD.
Cognoptix’s Sapphire II technology has demonstrated successful preclinical and clinical results with its current platform which consists of a laser eye scanning device combined with an ophthalmic ointment which specifically identifies β-amyloid, the Alzheimer’s-related protein found in the lens of the eye.
The company is interested in partnering with major pharmaceutical companies, licensing its laser eye scanning technology for use in the development of Alzheimer’s drugs, as an enabling technology for patient segmentation and monitoring in clinical trial.
Cognoptix, Inc.
100 Main Street, Suite 110
Concord, MA 01742
(978) 263-0005
Follow Biotech Showcase at @EBDGroup and @Demy_Colton and tag your posts with #BiotechShowcase.
